Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $338.5 million.

  • UNITED THERAPEUTICS's Accumulated Expenses rose 15.77% to $338.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $338.5 million, marking a year-over-year increase of 15.77%. This contributed to the annual value of $338.5 million for FY2024, which is 15.77% up from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Accumulated Expenses of $338.5 million as of FY2024, which was up 15.77% from $292.4 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Accumulated Expenses ranged from a high of $338.5 million in FY2024 and a low of $170.8 million during FY2021.
  • In the last 3 years, UNITED THERAPEUTICS's Accumulated Expenses had a median value of $292.4 million in 2023 and averaged $285.6 million.
  • In the last 5 years, UNITED THERAPEUTICS's Accumulated Expenses decreased by 6.62% in 2021 and then spiked by 32.20% in 2022.
  • Over the past 5 years, UNITED THERAPEUTICS's Accumulated Expenses (Yearly) stood at $182.9 million in 2020, then fell by 6.62% to $170.8 million in 2021, then soared by 32.20% to $225.8 million in 2022, then climbed by 29.50% to $292.4 million in 2023, then grew by 15.77% to $338.5 million in 2024.